Unknown

Dataset Information

0

CD44+ cells determine fenofibrate-induced microevolution of drug-resistance in prostate cancer cell populations.


ABSTRACT: Combinations of metabolic blockers (incl. fenofibrate) with chemotherapeutic drugs interfere with the drug-resistance of prostate cancer cells. However, their effect on cancer stem cells-dependent microevolution of prostate cancer malignancy remains unaddressed. Here, we hypothesize that the combined docetaxel/fenofibrate treatment prompts the selective expansion of cancer stem cells that affects the microevolution of their progenies. Accordingly, we adapted a combined in vitro/in vivo approach to identify biological and therapeutic consequences of this process. Minute subpopulations of docetaxel-resistant CD133high and/or CD44high cancer stem cell-like (SCL) cells were found in prostate cancer DU145 and PC3 cell populations. When pretreated with docetaxel, they readily differentiated into docetaxel-resistant CD44negative "bulk" cells, thus accounting for the microevolution of drug-resistant cell lineages. Combined docetaxel/fenofibrate treatment induced the generation of poly(morpho)nuclear giant cells and drug-resistant CD44high SCL cells. However, the CD44negative offspring of docetaxel- and docetaxel/fenofibrate-treated SCLs remained relatively sensitive to the combined treatment, while retaining enhanced resistance to docetaxel. Long-term propagation of drug-resistant SCL-derived lineages in the absence of docetaxel/fenofibrate resulted in their reverse microevolution toward the drug-sensitivity and invasive phenotype. Consequently, prostate tumors were able to recover from the combined docetaxel/fenofibrate stress after the initial arrest of their expansion in vivo. In conclusion, we have confirmed the potential of fenofibrate for the metronomic treatment of drug-resistant prostate tumors. However, docetaxel/fenofibrate-induced selective expansion of hyper-resistant CD44high SCL prostate cells and their "bulk" progenies prompts the microevolution of prostate tumor drug-resistance. This process can limit the implementation of metabolic chemotherapy in prostate cancer treatment.

SUBMITTER: Wrobel T 

PROVIDER: S-EPMC7756969 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

CD44<sup>+</sup> cells determine fenofibrate-induced microevolution of drug-resistance in prostate cancer cell populations.

Wróbel Tomasz T   Luty Marcin M   Catapano Jessica J   Karnas Elżbieta E   Szczygieł Małgorzata M   Piwowarczyk Katarzyna K   Ryszawy Damian D   Drabik Grażyna G   Zuba-Surma Ewa E   Siedlar Maciej M   Madeja Zbigniew Z   Elas Martyna M   Czyż Jarosław J  

Stem cells (Dayton, Ohio) 20200927


Combinations of metabolic blockers (incl. fenofibrate) with chemotherapeutic drugs interfere with the drug-resistance of prostate cancer cells. However, their effect on cancer stem cells-dependent microevolution of prostate cancer malignancy remains unaddressed. Here, we hypothesize that the combined docetaxel/fenofibrate treatment prompts the selective expansion of cancer stem cells that affects the microevolution of their progenies. Accordingly, we adapted a combined in vitro/in vivo approach  ...[more]

Similar Datasets

| S-EPMC9694160 | biostudies-literature
| S-EPMC6356694 | biostudies-literature
| S-EPMC3858556 | biostudies-other
| S-EPMC8312562 | biostudies-literature
| S-EPMC4694903 | biostudies-other
| S-EPMC7013615 | biostudies-literature
| S-EPMC4391735 | biostudies-literature
| S-EPMC7901483 | biostudies-literature
| S-EPMC3317155 | biostudies-literature
| S-EPMC8883996 | biostudies-literature